Affymax(R) Receives $5 Million Milestone Payment On Initiation Of Phase 3 Clinical Trials For Hematide™ In Japan
Affymax, Inc. (Nasdaq: AFFY) today announced that it has received a $5 million development milestone payment from Takeda Pharmaceutical Company as part of the companies' exclusive global agreement to develop and commercialize Hematide™, Affymax's investigational drug for the treatment of anemia in chronic renal failure patients...
- admin's blog
- Login or register to post comments
- Feed: medicalnewstodat.com-urology-feed
- Original article
Yahoo! BOSS
No related items were found.
Yahoo! BOSS Images
No related items were found.
